Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis
Logo

American Heart Association

  162
  0

Final ID:

Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
    • Author Disclosures:
    Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Discussant: SCAN-MP

Alexander Kevin

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Fontana Marianna, Maurer Mathew, Gillmore Julian, Bender Shaun, Aldinc Emre, Eraly Satish, Jay Patrick, Solomon Scott

More abstracts from these authors:
Red Flags in New Onset HFpEF that Should Raise Suspicion for Cardiac Amyloidosis

Alexander Kevin, Nativi-nicolau Jose, Raymer David

Evolving Baseline Risk in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials

Masri Ahmad, Nativi-nicolau Jose, Wright Richard, Betts Marissa, Lavoie Louis, Shree Aiswarya, Hennum Liana, Tamby Jean-francois, Falvey Heather, Dev Sandesh

You have to be authorized to contact abstract author. Please, Login
Not Available